Hyunseok Kang, MD, MPH

Dr.Hyunseok "Hyu" Kang is a medical oncologist and a clinician scientist focusing on head and neck cancers including squamous cell carcinomas of head and neck (SCCHN), salivary gland cancers, thyroid cancers and other rare cancers of head and neck. He is Professor of Medicine at Stanford University. He previously served as a faculty member at the University of California, San Francisco and at the Johns Hopkins University School of Medicine in Baltimore, MD.
Dr.Kang's research focus is development of clinical trials with novel therapeutic agents for patients with head and neck cancers. He pioneered in development of immune therapy in head and neck cancer and has conducted/participated a number of clinical trials with immune checkpoint inhibitors and targeted therapy agents with focus on precision oncology in head and neck squamous cell carcinomas and salivary gland cancers.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Pin TherapeuticsTopic:ConsultantDate added:04/12/2023Date updated:10/05/2025
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:BertisTopic:ConsultantDate added:04/12/2023Date updated:10/05/2025
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Remix TherapeuticsTopic:Scientific Advisory BoardDate added:04/12/2023Date updated:10/05/2025
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:LG ChemTopic:Scientific Advisory BoardDate added:04/12/2023Date updated:10/05/2025
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Cue BioTopic:ConsultantDate added:04/12/2023Date updated:10/05/2025
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Coherus BiosciencesTopic:Scientific Advisory BoardDate added:04/12/2023Date updated:10/05/2025
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:BayerTopic:ConsultantDate added:04/12/2023Date updated:10/05/2025

Facebook
X
LinkedIn
Forward